Elutia reports preliminary Q4 2025 revenue $3.3M (+16% YoY); eliminates $26.9M debt

ELUTIA INC.

2025-FY EPS reported $0.87 revenue$12,293,000

Preliminary Q4 net sales ~$3.3M, up 16% YoY, excluding divested BioEnvelope business.
Repaid full $26.9M debt to SWK Holdings, significantly cutting interest expense.
Cash on hand $36.3M; $8M escrow from BioEnvelope divestiture expected in 2026.
Plans FDA filing for NXT-41 base matrix in H1 2026, clearance H2 2026; NXT-41x clearance H1 2027.
CEO cites $88M EluPro divestiture to Boston Scientific as transformational, funding NXT-41x.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.